WEST BRIDGEWATER, Mass., Jan. 14 /PRNewswire-FirstCall/ -- Boston Biomedica, Inc. (Nasdaq: BBII) today announced the appointment of Mr. P. Thomas Vogel to the Company's Board of Directors effective Friday, January 9, 2004. In addition, the Company also announced that Mr. Vogel will serve on the Board's Audit and Compensation Committees. Mr. Vogel will fill the new Class II vacancy created by the unanimous decision by the Company's Board to expand its size from five to six members. The term for Class II members is set to expire at the 2004 Annual Meeting of Stockholders.
About Mr. Vogel
Mr. Vogel is the President and CEO of AdipoGenix, Inc, an early-stage drug discovery company focusing on obesity and metabolic diseases, with a unique approach to directly targeting the fat cell itself. From 1996 to 2000, Mr. Vogel was CEO and Director of Mosaic Technologies, Inc., an early-stage molecular biology company. In 1995, Mr. Vogel founded the Charlestown Group, a venture capital firm with a mission of investing in early-stage companies in medical and information technologies. Mr. Vogel worked with the Charlestown Group until 2000. From 1992 to 1995, Mr. Vogel was President of Fisher Scientific Company, a $1B laboratory supply distribution business. Mr. Vogel served as President of PB Diagnostics from 1991 to 1992, as President of Instrumentation Laboratory from 1990 to 1991, and as President of Serono Diagnostics from 1988 to 1990. Mr. Vogel was in the venture capital arena from 1982 to 1987. Prior to that, from 1974 to 1982, Mr. Vogel was at the Diagnostics Division of Abbott Laboratories, Inc., where he served as Divisional Vice President and General Manager of Diagnostic Products. Mr. Vogel began his professional career at Texas Instruments, Inc., where he held a number of key positions from 1964 to 1973, including plant management in Germany, Italy and Singapore.
Mr. Vogel graduated from the Georgia Institute of Technology with a Bachelor's Degree in Electrical Engineering and from The Wharton Business School with a Master's Degree in Business Administration.
Mr. R. Wayne Fritzsche, Chairman of the Board of Boston Biomedica, Inc., commented: "We are extremely pleased that Tom has joined the BBI Board of Directors. Tom's vast experience as a proven line management executive, early-stage venture investor, and senior manager in both large corporate and entrepreneurial organizations, is a wonderful resource for the Board as we continue to look at ways to increase shareholder value. Those who know Tom speak of his commitment to high-integrity decisions and people-oriented leadership. We welcome Tom to BBI, and believe that his appointment to the Board will serve all stakeholders of Boston Biomedica well."
About Boston Biomedica, Inc.
BBI provides products and services to the diagnostics and life sciences industry to evaluate, monitor, and ensure the quality of infectious disease test results, to improve the preparation of specimens for genomic/proteomic testing, and to safely store and retrieve rare and valuable biological specimens. The Company also manufactures reagents used in test kits and provides a broad range of routine and esoteric research services to governments and industry. BBI operates in three states, and conducts research in new applications for our patented Pressure Cycling Technology (PCT). In 2000, the Company launched Panacos Pharmaceuticals and maintains a significant passive investment in this novel antiviral drug development company.
Forward Looking Statements
Statements contained in this news release regarding the Company's or management's intentions, hopes, beliefs, expectations or predictions of the future are "forward-looking'' statements. It is important to note that the Company's actual results could differ materially from those projected in such forward-looking statements. There can be no assurance that Boston Biomedica will have future growth, that shareholder value will be increased, or that Mr. Vogel will have a significant impact on the success of the Company. Mr. Vogel's appointment as a Director is expected to expire on the date of the 2004 Annual Meeting of Stockholders and there can be no assurance he will be reelected to the Board at that meeting. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements, and risk factors, are contained in the Company's recent filings with the Securities and Exchange Commission of its Annual Report on Form 10-K for the year ended December 31, 2002, and on Form 10-Q's for the quarters ended March 31, June 30, and September 30, 2003. Copies of these documents may be obtained by contacting the Company or the SEC at www.sec.gov.
Visit us at our website http://www.bbii.com
Please email us at IR@bbii.com if you prefer to receive future announcements electronically
Investor Contact:
R. Wayne Fritzsche, Chairman
Kevin W. Quinlan, President & COO
Boston Biomedica, Inc.
(508) 580-1900 (T)
(508) 580-1110 (F)
SOURCE Boston Biomedica, Inc.